Humacyte (HUMA) said late Tuesday it priced an underwritten public offering of 25 million shares at $2 per share for expected gross proceeds of $50 million.
The company said the proceeds from the offering, expected to close on Thursday, will support the commercialization of Symvess for vascular trauma, further product development, and general corporate needs.
Humacyte granted the underwriters a 30-day option to purchase an additional about 3.8 million shares.
The company's shares were down more than 23% in premarket activity Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。